
|Articles|April 26, 2004
Vigamox gets FDA approval for a supplemental list of susceptible pathogens
Fort Lauderdale-The FDA has approved a supplemental list of susceptiblepathogens to the in vitro labeling of Vigamox ophthalmic solution, AlconLaboratories announced Monday.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
Iolyx Therapeutics and Laboratoires Théa enter into agreement over ILYX-002 for the treatment of OSD
2
Avisi Technologies treats first patient in SAPPHIRE trial for glaucoma
3
FDA approves Amneal Pharmaceuticals' cyclosporine ophthalmic emulsion 0.05%
4
Inflammasome Therapeutics completes phase 2 trial enrollment for K8 in GA
5















































.png)


